{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.41","upperLimit":"8.08","value":"7.29"},{"comment":"Median and Upper limit of 95% CI was not estimable due to short follow-up by participants.","groupId":"OG001","lowerLimit":"12.25","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"description":"TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of \\>=25% in level of serum M-protein from lowest response value and absolute increase must be \\>=0.5 g/dL; Increase of \\>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \\>=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \\>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \\>10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib 1.3 milligrams per square meter (mg/m\\^2) subcutaneous (SC) injection on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 milligrams (mg) orally (PO) on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles. Participants who met sponsor-confirmed disease progression eligibility criteria received daratumumab monotherapy as a subsequent antimyeloma therapy as follow: daratumumab 16 milligrams per kilogram (mg/kg) intravenous (IV) infusion or daratumumab SC injection (1800 mg fixed dose) weekly for the first 2 cycles, every 2 weeks from Cycle 3 to 6, and then every 4 weeks thereafter.","id":"OG000","title":"Bortezomib + Dexamethasone (Vd)"},{"description":"Participants received daratumumab 16 mg/kg IV infusion weekly or daratumumab SC injection (1800 mg fixed dose) for the first 3 cycles, on Day 1 of Cycles 4-8, and then every 4 weeks thereafter, bortezomib 1.3 mg/m\\^2 SC injection administration on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles.","id":"OG001","title":"Daratumumab + Bortezomib and Dexamethasone (DVd)"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documented evidence of progression or death due to PD whichever occurred first (approximately 6 years 9 months)","title":"Time to Disease Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}